Pralmorelin
Alternative Names: GHRP-2; GPA 748; Growth hormone releasing peptide 2; KP-102 D; KP-102 LNLatest Information Update: 02 Jun 2011
Price :
$50 *
At a glance
- Originator Polygen; Tulane University
- Developer Kaken Pharmaceutical; Wyeth
- Class Peptide diagnostics
- Mechanism of Action Ghrelin receptor agonists; Growth hormone releasing factor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Somatotropin deficiency
- Discontinued Short stature
Most Recent Events
- 16 Oct 2009 Wyeth has been acquired by Pfizer
- 12 Sep 2007 Pralmorelin is still in phase II trials for Short Stature in Japan
- 14 Mar 2005 Launched for Somatropin deficiency (diagnosis) in Japan (Parenteral)